Allopurinol Use and the Risk of Type 2 Diabetes Mellitus: A Meta-Analysis of Cohort Studies

Overview

Journal Dose Response

Publisher Sage Publications

Date 2022 Sep 12

PMID 36091718

Authors

Shih-Wei Lai

Bing-Fang Hwang

Yu-Hung Kuo

Chiu-Shong Liu

Kuan-Fu Liao

Affiliations

Soon will be listed here.

Abstract

Objective: To assess whether there is a relation between allopurinol use and the probability of type 2 diabetes mellitus (T2DM) in persons with gout and/or hyperuricemia.

Methods: According to the PRISMA 2020 guidelines, a meta-analysis was performed by searching literature published from 2000 to 2021 in two electronic databases (Ebscohost and PubMed). The end point was set as a new diagnosis ofT2DM between people with the use of allopurinol and people with non-use of allopurinol. The random-effects model was performed to evaluate the pooled hazard ratio (HR) with 95% confidence interval (CI) for T2DM associated with allopurinol use.

Results: Three cohort studies could meet the inclusion criteria in the meta-analysis. There was a high heterogeneity of the outcome between studies (I = 99%). The research duration ranged from 13 to 16 years. The subject number in each work ranged from 1114 to 138,652. A meta-analysis disclosed that there was not an association between allopurinol use and the risk of developing T2DM (pooled HR = 1.01 and 95%CI = .55-1.84).

Conclusions: The meta-analysis shows that no correlation is detected between allopurinol use and the risk of T2DM in individuals with gout and/or hyperuricemia. Because there are not enough eligible studies, the strength of evidence in our meta-analysis is weak. More cohort studies are needed to determine an association between use of allopurinol and the probability of T2DM for individuals with gout and/or hyperuricemia.

References

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Ghasemi A . Uric acid-induced pancreatic β-cell dysfunction. BMC Endocr Disord. 2021; 21(1):24. PMC: 7888074. DOI: 10.1186/s12902-021-00698-6. View

Johnson R, Nakagawa T, Sanchez-Lozada L, Shafiu M, Sundaram S, Le M . Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes. 2013; 62(10):3307-15. PMC: 3781481. DOI: 10.2337/db12-1814. View

Martinez-Sanchez F, Vargas-Abonce V, Guerrero-Castillo A, Santos-Villavicencio M, Eseiza-Acevedo J, Meza-Arana C . Serum Uric Acid concentration is associated with insulin resistance and impaired insulin secretion in adults at risk for Type 2 Diabetes. Prim Care Diabetes. 2020; 15(2):293-299. DOI: 10.1016/j.pcd.2020.10.006. View

Kuwabara M, Niwa K, Hisatome I, Nakagawa T, Roncal-Jimenez C, Andres-Hernando A . Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases: Five-Year Japanese Cohort Study. Hypertension. 2017; 69(6):1036-1044. PMC: 5426964. DOI: 10.1161/HYPERTENSIONAHA.116.08998. View

Nadwa E, Morcos G, Salama N, Shafik A . Comparing the Effects of Febuxostat and Allopurinol in an Animal Model of Metabolic Syndrome. Pharmacology. 2021; 106(9-10):564-572. DOI: 10.1159/000516495. View

Chen L, Lin M, Lai H, Hwang S, Chiou S . Uric acid: a surrogate of insulin resistance in older women. Maturitas. 2007; 59(1):55-61. DOI: 10.1016/j.maturitas.2007.10.006. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021; 134:178-189. DOI: 10.1016/j.jclinepi.2021.03.001. View

Krishnan E, Akhras K, Sharma H, Marynchenko M, Wu E, Tawk R . Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout. QJM. 2013; 106(8):721-9. PMC: 3713590. DOI: 10.1093/qjmed/hct093. View

10.

Wang L, Sawhney M, Zhao Y, Carpio G, Fonseca V, Shi L . Association Between Colchicine and Risk of Diabetes Among the Veterans Affairs Population With Gout. Clin Ther. 2015; 37(6):1206-15. DOI: 10.1016/j.clinthera.2015.03.010. View

11.

Jeon C, Lokken R, Hu F, van Dam R . Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care. 2007; 30(3):744-52. DOI: 10.2337/dc06-1842. View

12.

Dalbeth N, Phipps-Green A, Frampton C, Neogi T, Taylor W, Merriman T . Relationship between serum urate concentration and clinically evident incident gout: an individual participant data analysis. Ann Rheum Dis. 2018; 77(7):1048-1052. DOI: 10.1136/annrheumdis-2017-212288. View

13.

Wondmkun Y . Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications. Diabetes Metab Syndr Obes. 2020; 13:3611-3616. PMC: 7553667. DOI: 10.2147/DMSO.S275898. View

14.

Fang Y, Chung Y, Lin C, Lim Y . Association between Gout, Urate-Lowering Therapy, and Risk of Developing Type 2 Diabetes Mellitus: A Nationwide Population-Based Retrospective Cohort Study. Biomed Res Int. 2020; 2020:6358954. PMC: 7407011. DOI: 10.1155/2020/6358954. View

15.

Chang H, Lin Y, Lin M, Lan Y, Wang R . Associations between urate-lowering therapy and the risk of type 2 diabetes mellitus. PLoS One. 2019; 14(1):e0210085. PMC: 6322774. DOI: 10.1371/journal.pone.0210085. View

16.

Ismail L, Materwala H, Al Kaabi J . Association of risk factors with type 2 diabetes: A systematic review. Comput Struct Biotechnol J. 2021; 19:1759-1785. PMC: 8050730. DOI: 10.1016/j.csbj.2021.03.003. View

17.

Bonora E, Capaldo B, Cavallo Perin P, Del Prato S, De Mattia G, Frittitta L . Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutr Metab Cardiovasc Dis. 2007; 18(9):624-31. DOI: 10.1016/j.numecd.2007.05.002. View

18.

Jia G, Habibi J, Bostick B, Ma L, Demarco V, Aroor A . Uric acid promotes left ventricular diastolic dysfunction in mice fed a Western diet. Hypertension. 2014; 65(3):531-9. PMC: 4370431. DOI: 10.1161/HYPERTENSIONAHA.114.04737. View

19.

Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K . Association between serum uric acid and development of type 2 diabetes. Diabetes Care. 2009; 32(9):1737-42. PMC: 2732137. DOI: 10.2337/dc09-0288. View

20.

Takir M, Kostek O, Ozkok A, Elcioglu O, Bakan A, Erek A . Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. J Investig Med. 2015; 63(8):924-9. DOI: 10.1097/JIM.0000000000000242. View